Tag: Ophthalmology

No More Reading Glasses: KAMRA Vision Implants Treat Presbyopia

Presbyopia, the inability to see things up close, affects large portions of the population as we grow older. Most people with the condition end up using reading glasses, putting them on and off as necessary, while some people keep them on throughout the day and end up looking like that English teacher from your childhood that would read famous poems in front of the class. Soon there may be a new options for Americans that would rather avoid glasses all together.

The KAMRA Vision corneal inlay device has a camera-like aperture that automatically adjusts to change the depth of field of the image that falls on the retina. This allows implantees, after a 10 minute procedure using topical anesthesia, to go about their day without resorting to glasses and hopefully allowing them to regain their healthy vision. The device has been going through clinical trials, with some details on the latest below.

Read More »

Sneak Peek at AAO 2014

Dr Roger Steinert outlines the popular and not-to-miss sessions at this year’s American Academy of Ophthalmology meeting, and for those who can’t make it, the ‘virtual meeting’ is an option. Medscape Ophthalmology

ILUVIEN Eye Implant for Diabetic Macular Edema Finally FDA Approved (VIDEOS)

The FDA, finally, after three rejections, has given approval to pSivida‘s (Watertown, MA) ILUVIEN drug eluting eye implant for treating diabetic macular edema (DME). The device, about the length of, but much narrower than, a grain of rice (3.5 mm x 0.37 mm), is injected intravitreally using a syringe-like device. Once deployed, the device slowly releases fluocinolone acetonide (FAc), a corticosteroid, for the next three years to control inflammation within the eye and help slow down the effects of DME. The 25-gauge needle used during implantation is small enough for the wound to heal on its own following the procedure.

“FDA approval of ILUVIEN, our third FDA-approved product for retinal disease, provides an important treatment option for DME patients in the U.S., the majority of whose DME, despite anti-VEGF intra-ocular injections as frequently as monthly, is not optimally managed. ILUVIEN’s clinical trials showed that ILUVIEN can actually reverse vision loss in many DME patients. Another advantage of ILUVIEN over existing therapies is that a single injection provides sustained therapy for three years,” said Paul Ashton, Ph.D., president and chief executive officer of pSivida, in the announcement.

Read More »